Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterizing of Breast Cancer translational PEARL clinical trial

ABSTRACT: Characterizing of Breast Cancer translational PEARL clinical trial

PROVIDER: PRJNA927304 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23220000.fastq.gz	Fastqsanger.gz
	SRR23220100.fastq.gz	Fastqsanger.gz
	SRR23220200.fastq.gz	Fastqsanger.gz
	SRR23220300.fastq.gz	Fastqsanger.gz
	SRR23220400.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1820

Similar Datasets

Characterizing of Breast Cancer translational PEARL clinical trial

Project description:Introduction In HR+/HER2- metastatic breast cancer (MBC) is imperative to identify patients who respond poorly to CDK4/6i and to discover therapeutic targets to reverse this resistance. Non-luminal breast cancer subtype and high levels of CCNE1 are candidate biomarkers in this setting but further validation is needed. Methods We performed mRNA gene expression profiling and correlation with progression-free-survival (PFS) on 455 tumor samples included in the phase III PEARL study, that assigned HR+/HER2- MBC patients to receive palbociclib+ET vs capecitabine. ER+/HER2- breast cancer cell lines were used to generate and characterize resistance to palbociclib+ET. Results Non-luminal subtype was more prevalent in metastatic (14%) than in primary tumor samples (4%). Patients with non-luminal tumors had median PFS of 2.4months (m) with palbociclib+ET and 9.3m with capecitabine; HR:4.16, adjusted p-value<0.0001. Tumors with high CCNE1 expression (above median) had also worse median PFS with palbociclib+ET (6.2m) than with capecitabine (9.3m); HR:1.55, adjusted p-value=0.0036. In patients refractory to palbociclib+ET (PFS in the lower quartile) we found higher levels of Polo Like Kinase 1 (PLK1). In an independent data set (PALOMA3), tumors with high PLK1 show worse median PFS than those with low PLK1 expression under palbociclib+ET treatment. In ER+/HER2- cell line models we show that PLK1 inhibition reverses resistance to palbociclib+ET. Conclusion We confirm the association of non-luminal subtype and CCNE1 with resistance to CDK4/6i+ET in HR+ MBC. High levels of PLK1 mRNA identify patients with poor response to palbociclib, suggesting PLK1 could also play a role in the setting of resistance to CDK4/6i.

2023-01-26 | GSE223700 | GEO

Gene expression profile of FFPE samples collected with translational purposes from the MITO16/MaNGO-OV2 clinical trial

Project description:MITO16/MaNGO-OV2 (NCT01706120) is a multicenter, phase IV, single arm trial for advanced stage IIIB-IV or recurrent, previously untreated, ovarian cancer patients receiving carboplatin, paclitaxel plus bevacizumab for six 3-weekly cycles followed by bevacizumab single agent until progression or unacceptable toxicity up to a maximum of 22 total cycles. The trial that was specifically designed with a translational primary endpoint to explore if selected clinical and biological factors could identify ovarian cancer patients with better prognosis in terms of progression free survival and overall survival after combined first-line treatment with chemotherapy plus Bevacizumab. The translational study, designed together with the clinical trial, the translational study implicated the collection of patients’ tissue (formalin-fixed paraffin-embedded – FFPE) and blood samples. Gene expression profile was among the molecular analyses proposed on FFPE samples.

2023-04-19 | GSE208103 | GEO

Clinical Trial Sequencing Project (CTSP)

Project description:Clinical Trial Sequencing Project (CTSP)

| PRJNA331220 | ENA

Proteome characterization of the neoadjuvant clinical trial PROMIX

Project description:Proteome characterization of the neoadjuvant clinical trial PROMIX. https://www.clinicaltrials.gov/ct2/show/NCT00957125 Patients received six rounds of chemotherapy with epirubicin and docetaxel, and if PR or PD after the second course, bevacizumab.

2024-03-19 | PXD039529 | JPOST Repository

GOYA DLBCL clinical trial - RNASeq dataset

Project description:This dataset contains collected RNASeq data of 552 samples from the GOYA clinical trial.

2019-02-01 | GSE125966 | GEO

An integrated transcriptome analysis of immunological responses in pearl sac of pearl mussel Hyriopsis cumingii after mantle implantation

Project description:Our findings help us gain new insight into the immunological reactions induced by transplantation in pearl mussels and markedly bring us more clues about pearl sac formation, contributing to the novel development of management strategies for pearl culture.

2019-11-30 | GSE123069 | GEO

Array data from neoDDRD clinical trial

Project description:Array data from neoDDRD clinical trial

| PRJNA747706 | ENA

GOYA DLBCL clinical trial - RNASeq dataset

Project description:GOYA DLBCL clinical trial - RNASeq dataset

| PRJNA518119 | ENA

COBRA - clinical trial for colorectal cancer diagnosis from breath samples

Project description:COBRA - clinical trial for colorectal cancer diagnosis from breath samples

2019-08-23 | MSV000084227 | MassIVE

G-ToG clinical trial

Project description:Neisseria gonorrhoeae isolates collected during the G-ToG clinical trial